Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026

Tenaya Therapeutics, Inc.

2026-Q1 EPS reported -$0.09 revenue$225,000

Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
Alnylam collaboration: $10M upfront, up to $1.1B milestones; cash runway into H2 2027 inclusive of upfront.
TN-201 (HCM gene therapy): interim Cohort 2 data and Cohort 1 update expected Q2 2026; enrollment resumed after protocol amendments.
TN-401 (ARVC gene therapy): one-year Cohort 1 and initial Cohort 2 data to be presented at ASGCT May 15, 2026.
TN-301 (HDAC6i) granted Rare Pediatric and Orphan Drug Designation for DMD; preclinical data showed improved grip strength.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tenaya Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 6, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-208975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.